Literature DB >> 24088860

Irreproducible and uninterpretable Polymyxin B MICs for Enterobacter cloacae and Enterobacter aerogenes.

David Landman1, Julius Salamera, John Quale.   

Abstract

Carbapenem-resistant Enterobacter species are emerging nosocomial pathogens. As with most multidrug-resistant Gram-negative pathogens, the polymyxins are often the only therapeutic option. In this study involving clinical isolates of E. cloacae and E. aerogenes, susceptibility testing methods with polymyxin B were analyzed. All isolates underwent testing by the broth microdilution (in duplicate) and agar dilution (in duplicate) methods, and select isolates were examined by the Etest method. Selected isolates were also examined for heteroresistance by population analysis profiling. Using a susceptibility breakpoint of ≤2 μg/ml, categorical agreement by all four dilution tests (two broth microdilution and two agar dilution) was achieved in only 76/114 (67%) of E. cloacae isolates (65 susceptible, 11 resistant). Thirty-eight (33%) had either conflicting or uninterpretable results (multiple skip wells, i.e., wells that exhibit no growth although growth does occur at higher concentrations). Of the 11 consistently resistant isolates, five had susceptible MICs as determined by Etest. Heteroresistant subpopulations were detected in eight of eight isolates tested, with greater percentages in isolates with uninterpretable MICs. For E. aerogenes, categorical agreement between the four dilution tests was obtained in 48/56 (86%), with conflicting and/or uninterpretable results in 8/56 (14%). For polymyxin susceptibility testing of Enterobacter species, close attention must be paid to the presence of multiple skip wells, leading to uninterpretable results. Susceptibility also should not be assumed based on the results of a single test. Until the clinical relevance of skip wells is defined, interpretation of polymyxin susceptibility tests for Enterobacter species should be undertaken with extreme caution.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24088860      PMCID: PMC3838098          DOI: 10.1128/JCM.02129-13

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  30 in total

1.  Early dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007.

Authors:  Mariana Castanheira; Lalitagauri M Deshpande; Dilip Mathai; Jan M Bell; Ronald N Jones; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

2.  In vitro studies of polymyxin.

Authors:  E A BLISS; C A CHANDLER; E B SCHOENBACH
Journal:  Ann N Y Acad Sci       Date:  1949-06-22       Impact factor: 5.691

3.  Genetic relatedness of multidrug-resistant Acinetobacter baumannii endemic to New York City.

Authors:  D Landman; M Butnariu; S Bratu; J Quale
Journal:  Epidemiol Infect       Date:  2008-05-27       Impact factor: 2.451

Review 4.  The Salmonella PmrAB regulon: lipopolysaccharide modifications, antimicrobial peptide resistance and more.

Authors:  John S Gunn
Journal:  Trends Microbiol       Date:  2008-05-06       Impact factor: 17.079

5.  Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS.

Authors:  Lucía Fernández; W James Gooderham; Manjeet Bains; Joseph B McPhee; Irith Wiegand; Robert E W Hancock
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

6.  Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production.

Authors:  Jennifer H Moffatt; Marina Harper; Paul Harrison; John D F Hale; Evgeny Vinogradov; Torsten Seemann; Rebekah Henry; Bethany Crane; Frank St Michael; Andrew D Cox; Ben Adler; Roger L Nation; Jian Li; John D Boyce
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

7.  Involvement of pmrAB and phoPQ in polymyxin B adaptation and inducible resistance in non-cystic fibrosis clinical isolates of Pseudomonas aeruginosa.

Authors:  Kristen N Schurek; Jorge L M Sampaio; Carlos R V Kiffer; Sumiko Sinto; Caio M F Mendes; Robert E W Hancock
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

8.  Alterations in two-component regulatory systems of phoPQ and pmrAB are associated with polymyxin B resistance in clinical isolates of Pseudomonas aeruginosa.

Authors:  Kaddy Barrow; Dong H Kwon
Journal:  Antimicrob Agents Chemother       Date:  2009-09-14       Impact factor: 5.191

9.  Comparative evaluation of the VITEK 2, disk diffusion, etest, broth microdilution, and agar dilution susceptibility testing methods for colistin in clinical isolates, including heteroresistant Enterobacter cloacae and Acinetobacter baumannii strains.

Authors:  Jerome R Lo-Ten-Foe; Anne Marie G A de Smet; Bram M W Diederen; Jan A J W Kluytmans; Peter H J van Keulen
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

10.  Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system.

Authors:  Mark D Adams; Gabrielle C Nickel; Saralee Bajaksouzian; Heather Lavender; A Rekha Murthy; Michael R Jacobs; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2009-06-15       Impact factor: 5.191

View more
  22 in total

1.  Colistin resistance in Enterobacter spp. isolates in Korea.

Authors:  Yoon-Kyoung Hong; Ji-Young Lee; Kwan Soo Ko
Journal:  J Microbiol       Date:  2018-06-01       Impact factor: 3.422

Review 2.  Antimicrobial heteroresistance: an emerging field in need of clarity.

Authors:  Omar M El-Halfawy; Miguel A Valvano
Journal:  Clin Microbiol Rev       Date:  2015-01       Impact factor: 26.132

Review 3.  Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations.

Authors:  Fereshteh Ezadi; Abdollah Ardebili; Reza Mirnejad
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

Review 4.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

Authors:  Laurent Poirel; Aurélie Jayol; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

5.  Susceptibility Testing for the Polymyxins: Two Steps Back, Three Steps Forward?

Authors:  Shawn Vasoo
Journal:  J Clin Microbiol       Date:  2017-07-19       Impact factor: 5.948

Review 6.  Polymyxin Resistance in Gram-negative Pathogens.

Authors:  Pavithra Srinivas; Kaitlyn Rivard
Journal:  Curr Infect Dis Rep       Date:  2017-09-11       Impact factor: 3.725

7.  mcr-3 and mcr-4 Variants in Carbapenemase-Producing Clinical Enterobacteriaceae Do Not Confer Phenotypic Polymyxin Resistance.

Authors:  Jeanette W P Teo; Marimuthu Kalisvar; Indumathi Venkatachalam; Oon Tek Ng; Raymond T P Lin; Sophie Octavia
Journal:  J Clin Microbiol       Date:  2018-02-22       Impact factor: 5.948

8.  Colistin and Polymyxin B Susceptibility Testing for Carbapenem-Resistant and mcr-Positive Enterobacteriaceae: Comparison of Sensititre, MicroScan, Vitek 2, and Etest with Broth Microdilution.

Authors:  Ka Lip Chew; My-Van La; Raymond T P Lin; Jeanette W P Teo
Journal:  J Clin Microbiol       Date:  2017-06-07       Impact factor: 5.948

Review 9.  Rescuing the Last-Line Polymyxins: Achievements and Challenges.

Authors:  Sue C Nang; Mohammad A K Azad; Tony Velkov; Qi Tony Zhou; Jian Li
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

10.  Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae.

Authors:  Victor I Band; Emily K Crispell; Brooke A Napier; Carmen M Herrera; Greg K Tharp; Kranthi Vavikolanu; Jan Pohl; Timothy D Read; Steven E Bosinger; M Stephen Trent; Eileen M Burd; David S Weiss
Journal:  Nat Microbiol       Date:  2016-05-09       Impact factor: 17.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.